Apellis Pharmaceuticals, Inc.APLSNASDAQ
Loading
Free Cash Flow Growth AcceleratingAccelerating
Percentile Rank100
3Y CAGR+159.1%
5Y CAGR+46.9%
Studio
Year-over-Year Change

Year-over-year free cash flow growth rate

3Y CAGR
+159.1%/yr
Annual compound
5Y CAGR
+46.9%/yr
Recent acceleration
Percentile
P100
Near historical high
vs 5Y Ago
6.8x
Strong expansion
Streak
2 yr
Consecutive growthAccelerating
PeriodValue
2025151.00%
202485.18%
2023-15.57%
20228.68%
2021-240.08%
202022.05%
2019-62.17%
2018-181.66%
2017-79.19%
2016-37.90%